Halozyme director Appelhans reports no share holdings

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. (HALO) filed an initial statement of beneficial ownership for director Dannielle Appelhans. The Form 3 indicates her status as a director but does not report any specific equity holdings or transactions at this time. The filing also includes an Exhibit 24 Power of Attorney authorization.

Key Terms

Power of Attorney, Exhibit 24

2 terms

Power of Attorney regulatory

"Exhibit List: Exhibit 24 - Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

Exhibit 24 regulatory

"Exhibit List: Exhibit 24 - Power of Attorney"

FAQ

What does the latest Form 3 filing reveal about HALO (HALOZYME THERAPEUTICS, INC.)?

It identifies Dannielle Appelhans as a director of HALOZYME THERAPEUTICS, INC. and serves as her initial statement of beneficial ownership, without listing any specific holdings or transactions.

Does the HALO Form 3 show any HALOZYME stock transactions by Dannielle Appelhans?

No. The Form 3 data show no reported transactions, with buy, sell, acquire, and dispose counts all at zero and no holding entries listed.

Are any share holdings reported for Dannielle Appelhans in HALO stock on this Form 3?

No specific share holdings are reported. The filing’s summary shows 0 holding entries, indicating no positions are detailed in this initial statement.

What role does Dannielle Appelhans have at HALOZYME THERAPEUTICS, INC. (HALO)?

The Form 3 identifies Dannielle Appelhans as a director of HALOZYME THERAPEUTICS, INC., with no officer title or 10% owner status indicated.

What is the Exhibit 24 mentioned in the HALO Form 3 filing?

The remarks section lists Exhibit 24 - Power of Attorney, indicating a Power of Attorney authorizing actions related to this Form 3 filing on behalf of the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:55 PM Accepted by SEC EDGAR 08/21/2026 - 04:54 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Appelhans Dannielle

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/14/2026

3. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ James R. Oehler, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)